Pfizer: We obtained a global license to distribute oral corona treatment

 The "Pfizer" company announced that it had obtained a global license deal to treat the Corona virus, after the success of clinical tests conducted for the first pill of its kind that it produced to treat coronary disease, and the emergence of its high efficacy.

Today, Tuesday, the company said, according to “Agence France Presse”: “A deal has been obtained to make the oral anti-coronavirus drug available at a cheaper price in poor countries, if it passes trials and regulatory approval.”

Earlier in the day, Pfizer announced the signing of an agreement with a United Nations-backed group to allow other manufacturers to make an experimental coronavirus drug.

The company explained in a statement that it will grant a license to the antiviral drug to the Geneva-based Medicines Patent Pool, which will allow generic drug companies (which produce similar pharmaceutical materials) to produce the drug for use in 95 countries, which constitute about 53% of the world's population.

And the company announced, on Friday, November 5, that the drug called “Paxlovid” succeeded by 89% in reducing the risk of transferring patients to hospitals or the death of many adults with “Covid-19”, who are most at risk of severe illness.

The company explained that the results of this clinical test, which took place in the middle to late stage, are so good that Pfizer will stop looking for new people to undergo tests.

In turn, British Health Minister Sajid Javid praised, on Friday, the successful results of the trial of the pills company "Pfizer".

According to Al-Hurra channel, Sajid Javid said: “If approved, this could be another important weapon to combat the virus along with vaccines and other treatments, including “molnopiravir”, which the United Kingdom was the first country in the world to approve this week.

And the United Kingdom had bought 250,000 boxes of the drug, which Pfizer said is effective in reducing the risk of transferring patients to hospitals, or the death of many adults with Covid-19, who are most at risk of severe illness.